Long QT Syndrome

Shirley, New York, September 3, 2026 American Regent, Inc. has initiated a voluntary nationwide recall of three lots of...

San Francisco, California, September 3, 2026 Thryv Therapeutics Inc., a clinical-stage biopharmaceutical company developing selective SGK1 inhibitors, has entered...

San Francisco, California, USA – April 22, 2026 In a significant advancement for rare cardiac disease therapeutics, Thryv Therapeutics...